Finally, therapy using anti–PD-1 and anti–CTLA-4 monoclonal antibodies, important checkpoints of the immune response, has demonstrated to play an important and valid approach to treat some types of cancer (129), where it is assumed primarily to enhance CD8+ T cell–mediated tumor destruction. The gene discussed is CTLA4; the disease is cancer.